Exiris makes use of several platform technologies for target identification and validation. In addition, Exiris is developing its own antibody and drug conjugate technologies: Cancer stem cell platform, Drug conjugate technology and Antibody technologies.

read more


Exiris provides contract research services and collaborative development agreements using its innovative technology platforms: CSC Platform, Target ID, Drug-Conjugate platform, Custom human mAb production, Biomarker discovery and (…)

read more

New data presented at the Peptides and Conjugates for Tumor Targeting, Therapy and Diagnosis, Riminipeptide2018 Congress

Exiris presents data on novel cytotoxic peptide-drug conjugates for tumor targeted therapy, generated in collaboration with the University of Bielefeld and Italfarmaco within the Horizon.. Read More →

Contact us

Exiris srl

Via Giano Della Bella 34
00162 Roma

Legal address:
Via Savona 6
00182 Rome – Italy

+39 06 49904451
+39 06 49904457